Evaluating neutrophils in patients with Antisynthetase Syndrome
Evaluation of Circulating Neutrophils in Antisynthetase Syndrome: a Multicenter Retrospective Study
This study is trying to see if measuring certain white blood cells in people with Antisynthetase Syndrome can help understand how severe their disease is, especially when it affects the lungs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Nancy) |
| Trial ID | NCT05989399 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the role of circulating neutrophils in patients diagnosed with Antisynthetase Syndrome (ASyS), a rare connective tissue disease. The study will assess whether the levels of circulating neutrophils can serve as a biomarker for disease severity, particularly in relation to interstitial lung disease, which is a common and serious complication of ASyS. By analyzing the neutrophil levels, researchers hope to gain insights into the inflammatory processes involved in ASyS and their correlation with disease activity. The study will include patients diagnosed according to Connors criteria while excluding those with active infections or certain cancer diagnoses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Antisynthetase Syndrome according to Connors criteria.
Not a fit: Patients with active infections, evolving cancers, or those who have started corticosteroid therapy prior to neutrophil evaluation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a simple and accessible biomarker for assessing disease severity in patients with Antisynthetase Syndrome.
How similar studies have performed: There is limited data on the evaluation of circulating neutrophils in Antisynthetase Syndrome, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with ASyS diagnosis according to Connors criteria Exclusion Criteria: * Active infection at ASyS diagnosis * Evolutive cancer at ASyS diagnosis * Corticosteroid therapy initiation before circulating neutrophils evaluation
Where this trial is running
Nancy
- CHU Nancy — Nancy, France (Recruiting)
Study contacts
- Principal investigator: Paul Decker, MD — Chu Nancy
- Study coordinator: Paul Decker, MD
- Email: p.decker@chru-nancy.fr
- Phone: +33383157240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.